FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $47.61, for a total transaction of $1,839,459.96. Following the transaction, the chief executive officer now directly owns 3,029,887 shares of the company’s stock, valued at approximately $144,252,920.07. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of FibroGen Inc (NASDAQ FGEN) traded up $0.05 on Monday, hitting $46.20. 663,105 shares of the stock were exchanged, compared to its average volume of 565,771. The firm has a market capitalization of $3,800.00, a price-to-earnings ratio of -22.76 and a beta of 1.55. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen Inc has a 1-year low of $21.05 and a 1-year high of $60.15.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of FibroGen by 15.1% during the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after buying an additional 761,421 shares during the last quarter. BlackRock Inc. raised its position in FibroGen by 12.3% in the second quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock worth $161,545,000 after purchasing an additional 546,587 shares in the last quarter. FMR LLC raised its position in FibroGen by 96.9% in the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after purchasing an additional 1,641,423 shares in the last quarter. State Street Corp raised its position in FibroGen by 16.4% in the second quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock worth $56,962,000 after purchasing an additional 248,922 shares in the last quarter. Finally, Hillhouse Capital Management Ltd. raised its position in FibroGen by 75.0% in the second quarter. Hillhouse Capital Management Ltd. now owns 1,750,000 shares of the biopharmaceutical company’s stock worth $56,525,000 after purchasing an additional 750,000 shares in the last quarter. 57.23% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have recently commented on the stock. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. ValuEngine lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 price objective on shares of FibroGen in a research report on Thursday, September 14th. Mizuho assumed coverage on shares of FibroGen in a research report on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price objective for the company. Finally, Jefferies Group reaffirmed a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $65.67.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/fibrogen-inc-fgen-ceo-sells-1839459-96-in-stock/1799090.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.